Amlodipine/hydrochlorothiazide/losartan
Alternative Names: amlodipine/HCTZ/losartan; amlodipine/losartan/hydrochlorothiazide; hydrochlorothiazide/amlodipine/losartan; losartan/amlodipine/hydrochlorothiazide; MK-0954ELatest Information Update: 03 Aug 2015
At a glance
- Originator Merck Sharp & Dohme
- Class Antihypertensives; Benzothiadiazines; Biphenyl compounds; Dihydropyridines; Heart failure therapies; Imidazoles; Ischaemic heart disorder therapies; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Thiazide diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 03 Aug 2015 No recent reports on development identified - Phase-III for Hypertension in Japan (PO)
- 26 Apr 2012 Merck completes a phase III trial in Hypertension in Japan (NCT01302691)
- 12 Jan 2012 Merck completes enrolment in its phase III trial for Hypertension in Japan (NCT01302691)